Arrowhead Research | ARWR - 债务



金融业
股票价格
USD
资产
USD 2.27B
现金及等价物
USD 201.64M
流动资产
USD 1.84B
流动负债
USD 295.22M
债务
USD 312.77M
EBIT
USD -141.26M
EBITDA
USD 57.17M
员工
711
EPS每股收益
USD -0.93
股本和储备
USD 613.98M
销售毛利
USD 264.03M
债务利息支出
USD 22.51M
利息收入
USD 9.69M
贷款资金
USD 1.23B
市值
USD 9.4B
净收入
USD -132.73M
营业费用
USD 215M
营业利润
USD -141.26M
普通股股本
USD 137.39M
PE价格收益
41.67
税前利润
USD 28.27M
销售收入
USD 73.74M
销售和管理费用
USD 41.74M
股票
USD -173.09M
贸易债权人
USD 30.75M
应收帐款人
USD 15.69M


债务 更改 日
Agios Pharmaceuticals USD 40.21M 4.31M 2025-12
Alnylam Pharmaceuticals USD 1.28B 30.06M 2025-12
Anika Therapeutics USD 0 0 2025-03
Arrowhead Research USD 312.77M 53.52M 2025-12
Heron Therapeutics USD 149.65M 157K 2024-09
Incyte USD 39.43M 982K 2026-03
Ionis Pharmaceuticals USD 2.34B 9.5M 2026-03
Ligand Pharmaceuticals USD 451.49M 494K 2025-12
Merck USD 49.34B 7.97B 2025-12
Moderna USD 1.31B 571M 2025-12
Nektar Therapeutics USD 0 0 2022-06
Novartis USD 47B 11.62B 2026-03
Sarepta Therapeutics USD 1.04B 210.44M 2025-12
TG Therapeutics USD 253.71M 8.37M 2025-12
Ultragenyx Pharmaceutical USD 36M 2.17M 2025-12
Vertex Pharmaceuticals USD 1.99B 44M 2026-03
Xencor USD 187.75M 118.48M 2025-12